



USSN: 10/533,388
Atty. Docket No.: 255/225US

IPE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/533,388

Inventors: Andrew Young, et al.

International

Filing Date: July 13, 2000

Title: THE USE OF MEMBRANES, CELLS AND
TISSUE FROM THE AREA POSTREMA TO
IDENTIFY THERAPEUTIC COMPOUNDS

Confirmation No.: 7065

TC/A.U.: not assigned

Examiner: not assigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In compliance with 37 C.F.R. §1.56, the patent documents listed on the attached Form PTO/SB/08A are being submitted herewith for consideration by the Examiner. In accordance with 37 C.F.R. 1.98, a copy of each of the listed items, other than U.S. Patents and U.S. Patent Application Publications, is included herewith.

The references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

04/24/2006 EAYALEW1 00000020 010535 10533388

01 FC:1806 180.00 DA

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8a

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient First Class postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

13 April 2006
Date of Deposit

Monica Benson
Signature of Person Mailing Paper

Monica Benson
Name of Person Mailing Paper

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. 1.97(b) in that Applicants believe that it is being filed before the mailing date of the first Office Action on the merits. Accordingly, neither a statement nor a fee under 37 C.F.R. 1.97(c) is required. If Applicants are mistaken, and the mailing date of the first Office Action on the merits precedes the filing of this Supplemental Information Disclosure Statement, Applicants authorize that the fee due under 37 C.F.R. 1.17(p) be charged to Deposit Account No 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: 13 April 2006

By: Karen R. Zachow
Karen R. Zachow, Ph.D.
Registration No. 46,332

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: (858) 552-2200
Facsimile: (858) 552-1936



Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

				Complete if Known	
				Application Number	10/533,388
				International Filing Date	July 13, 2000
				First Named Inventor	Young, et al.
				Art Unit	not assigned
				Examiner Name	not assigned
Sheet	1	of	2	Attorney Docket No.	255/225US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,264,372		11-23-1993	Beaumont, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number -Kind Code ⁴ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL letters), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		EDWARDS, et al., <i>Neurogastroenterol Motil.</i> 1998; 10(4): 365	
		HASSEN, et al., "Delta versus mu receptors: cardiovascular and respiratory effects of opiate agonists microinjected into nucleus tractus solitarius of cats" <i>Regulatory Peptides</i> 1982, vol. 4, pgs. 299-309	
		HERRICK-DAVIS, et al., "Detection and characterization of a 5HT1D serotonin receptor-GTP binding protein interaction in porcine and bovine brain", <i>SYNAPSE</i> 1989, vol. 3, pgs. 325-330	
		International Search Report, International Application No. PCT/US00/19497, Young, et al., Publication Date May 10, 2001, pgs. 1-38	
		LI, et al., "Manipulations of metabolic fuel availability alter estrous behavior and neural estrogen receptor immunoreactivity in Syrian hamsters", <i>Endocrinology</i> 1994, vol. 135, pgs. 240-247	
		LUTZ, et al., "Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of Amylin and Calcitonin gene-related peptide (CGRP) in rats", <i>Peptides</i> 1998, vol. 19, no. 2, pgs. 309-17	
		MILLER, et al., "Membrane-bound and solubilized brain 5HT3 receptors: improved radioligand binding assays using bovine area postrema or rat cortex and the radioligands 3H-GR65630, 3H-BRL43694, and 3H-LY278584", <i>SYNAPSE</i> 1992, vol. 11, no. 1, pgs. 58-66	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 07/31/2006 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

				Complete if Known	
				Application Number	10/533,388
				International Filing Date	July 13, 2000
				First Named Inventor	Young, et al.
				Art Unit	not assigned
				Examiner Name	not assigned
Sheet	2	of	2	Attorney Docket No.	255/225US

	PANICKER, et al., "Insulin-induced repartitioning of metabolic fuels inhibits hamster estrous behavior: role of area postrema", Am. J. Physiol. 1998, vol. 274 (Regulatory Integrative and Comp. Physiol. 43), pgs. R1094-R1098	
	RAUCH, et al., "Blood-borne Amylin stimulates water intake via central action on neurons of the subfornical organ", Pfluegers Archiv. 1997, Suppl. Vol. 433, pg. 618	
	RHODES, et al., "WAY 100289: pharmacological profile of a novel 5-HT3 receptor antagonist", Drug Development Research 1993, vol. 28, pgs. 128-140	
	RIEDIGER, et al., "Central nervous targets for pancreatic Amylin", Pfluegers Archiv. 1999, Suppl. vol. 437, no. 5, pg. R142	
	RITTER, et al., "Cooperation of vagal and central neural systems in monitoring metabolic events controlling feeding behavior", Neuroanatomy and Physiol. of Abdominal Vagal Afferents 1999, pgs. 249-277	
	SIRETT, et al., "Distribution of Angiotensin II Receptors in Rat Brain", Brain Research 1977, vol. 122, pgs. 299-312	
	WADE, et al., "Control of fertility by metabolic cues", Am. J. Physiol. 1996, Endo. Metab. 33, vol. 270, pgs. E1-E19	
	WHELAN, et al., "Synthesis and structural, conformational, biochemical, and pharmacological study of new compounds derived from Tropane-3-spiro 4'(5')-imidazoline as potential 5-HT3 receptor antagonists"; Journal of Pharmaceutical Sciences 1995, vol. 84, no. 1, pgs. 101-106	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.